Filter Results :

Your search for T-Cell returned 30 reports

Sort by


Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H1, 2016

29 Jun 2016  |  Published by:  GlobalData
SummaryGlobalData's clinical trial report, Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H1, 2016 provides an overview of Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy clinical trials scenario. This report provides to...

$ 2,500.00

Read More

T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) - Pipeline Review, H1 2016

28 Jun 2016  |  Published by:  Global Markets Direct
SummaryGlobal Markets Directs, T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) - Pipeline Review, H1 2016, provides in depth analysis on T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) targete...

$ 3,500.00

Read More

Cutaneous T-Cell Lymphoma Global Clinical Trials Review, H1, 2016

31 May 2016  |  Published by:  GlobalData
Summary“Cutaneous T-Cell Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of Cutaneous T-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Cutaneous T-Cell Lymphoma. Report includes an overview of trial numbers and the...

$ 2,500.00

Read More

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2016

18 May 2016  |  Published by:  Global Markets Direct
Summary‘Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell ...

$ 3,500.00

Read More

T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

11 May 2016  |  Published by:  La Merie Business Intelligence
Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Des...

$ 2,400.00

Read More

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016

30 Mar 2016  |  Published by:  Global Markets Direct
SummaryGlobal Markets Direct’s, ‘Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cel...

$ 2,000.00

Read More

Cutaneous T-Cell Lymphoma Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

01 Jan 2016  |  Published by:  DelveInsight
Summary'Cutaneous T-Cell Lymphoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014', report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for A...

$ 2,000.00

Read More

Peripheral T-Cell Lymphomas (PTCL) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

01 Jan 2016  |  Published by:  DelveInsight
Summary'Peripheral T-Cell Lymphomas (PTCL)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014', report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understand...

$ 2,000.00

Read More

T-Cell Leukemia Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

01 Jan 2016  |  Published by:  DelveInsight
Summary'T-Cell Leukemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014', report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufac...

$ 2,000.00

Read More

T-Cell Lymphomas Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

01 Jan 2016  |  Published by:  DelveInsight
Summary'T-Cell Lymphomas- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014', report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufa...

$ 2,000.00

Read More

Cutaneous T-Cell Lymphoma-Pipeline Insights, 2016

01 Jan 2016  |  Published by:  DelveInsight
Summary Cutaneous T-Cell Lymphoma- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Cutaneous T-Cell Lymphoma. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and...

$ 1,250.00

Read More

Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2016

01 Jan 2016  |  Published by:  DelveInsight
Summary Peripheral T-Cell Lymphomas (PTCL)- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Peripheral T-Cell Lymphomas (PTCL). The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations...

$ 1,250.00

Read More

T-Cell Leukemia-Pipeline Insights, 2016

01 Jan 2016  |  Published by:  DelveInsight
Summary T-Cell Leukemia- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the T-Cell Leukemia. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals...

$ 1,250.00

Read More

T-Cell Lymphomas-Pipeline Insights, 2016

01 Jan 2016  |  Published by:  DelveInsight
Summary T-Cell Lymphomas- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the T-Cell Lymphomas. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing dea...

$ 1,250.00

Read More

Cutaneous T-Cell Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

01 Jan 2016  |  Published by:  DelveInsight
SummaryDelveInsight’s, Cutaneous T-Cell Lymphoma-API Insights, 2015,report provides Cutaneous T-Cell Lymphoma drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF fi...

$ 1,250.00

Read More
Total 30 records.